Primary Prevention Hepatocellular Carcinoma by Metformin (METFOVIR)
PRIMARY PREVENTION OF HEPATOCELLULAR CARCINOMA BY METFORMIN IN PATIENTS WITH VIRAL C CIRRHOSIS : PROSPECTIVE MULTICENTER STUDY, RANDOMIZED CONTROL TRIAL. Ancillary Study of the ANRS CO12 CirVir Cohort
Sponsor: ANRS, Emerging Infectious Diseases
Terminated
Decision of investigator
Other terminated trials from ANRS, Emerging Infectious Diseases
- HIV Seropositivity · Mar 2023
- HIV-1-infection · Phase PHASE1/PHASE2 · Jul 2019
- HIV Infection · Sep 2016
- HIV-1 Infection · Phase PHASE3 · Sep 2015
- HIV Infected Women · Phase NA · Jan 2015
See all terminations from ANRS, Emerging Infectious Diseases
Listed as NCT02319200, this PHASE3 trial focuses on Cirrhosis and Hepatitis C, Chronic and remains terminated or withdrawn. Sponsored by ANRS, Emerging Infectious Diseases, it has been updated 7 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ANRS, Emerging Infectious Diseases
- Assistance Publique - Hôpitaux de Paris
For direct contact, visit the study record on ClinicalTrials.gov .